

February 28, 2025

Company: Chiome Bioscience Inc.  
Representative: Shigeru Kobayashi, President & CEO  
(Code: 4583, Tokyo Stock Exchange Growth)

**Announcement of a collaborative exploratory research agreement with OmniAb, Inc.**

Chiome Bioscience Inc. ("Chiome") has entered into a collaborative exploratory research agreement with OmniAb, Inc. (Headquarters: Emeryville, California, USA, "OmniAb") to evaluate potential technology synergies related to bispecific antibody generation.

Chiome has been developing cell surface display technology to efficiently screen for bispecific antibodies using our proprietary technology called ADLib<sup>®</sup> system.

In this collaborative exploratory research, we are aiming to implement a high throughput bispecific antibody screening system that will enable rapid evaluation of many combinations of candidate monoclonal antibody arms that have been discovered by OmniAb using its OmniClic<sup>®</sup> transgenic chicken platform.

In addition, we are planning to use our novel technology in our Integrated Drug Discovery (IDD) business we are about to launch (antibody development platform business). We believe this will lead to strengthening our profitability.

The impact on financial results for the fiscal year ending December 2025 will be minimal.

<OmniAb Inc.>

OmniAb, Inc. (Headquarters: Emeryville, California, USA, CEO: Matt Foehr) licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. OmniClic<sup>®</sup> is a common light chain technology to facilitate the generation of bispecific antibodies.

<Bispecific antibody>


The bispecific antibody is one of new antibody modalities that enables the design of therapeutic antibodies based on novel mechanisms of action. Rapidly developed in recent years, it is at the core of next-generation antibody drug discovery. It can create highly flexible antibodies that enable rapid evaluation of various samples, such as combining targets or identifying the most suitable combination with parent monoclonal antibodies, making them necessary for efficient screening.

<The importance of this technology for our IDD business>

The IDD business offers solutions for various R&D needs from partner companies, including pharmaceutical companies based on our knowledge, experience and technology, and advancing to collaborative antibody drug discovery to acquire milestone revenue. This research results will be a key factor to promote the IDD business.

## Antibody Drug Discovery Platform: IDD (Integrated Drug Discovery)

Developing an end-to-end platform for antibody drug discovery projects from screening, to in vitro/vivo evaluation, CMC, IND and early phase clinical. In addition to in-house drug discovery and drug discovery support business, we are launching an IDD business that offers various solutions to our partner companies using our drug discovery research and development experience, knowledge, and technology.



The collaborative exploratory research aims to implement a high throughput bispecific antibody screening system. This will enable the flexible design of antibodies capable of binding to two different targets, which is a crucial element in advancing future IDD-type business.

[Inquiries]

Chiome Bioscience Inc. Investor Relations

E-mail: [ir@chiome.co.jp](mailto:ir@chiome.co.jp)